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Abstract 
Objective  
To determine if pharmacy service intervention can lead to enhanced adherence to primary and 
secondary cardiovascular medication and to identify features of interventions that have been 
found to be effective and feasible.  
Methods  
A systematic search of studies related to pharmacy service interventions on adherence and 
outcomes of cardiovascular diseases was performed using the following databases: Pubmed 
central UK, Pubmed, Cochrane Library, CINHAL, PsycINFO, EMBASE, International 
Pharmaceutical Abstracts and Google Scholar for the period from 01/01/1990 to 19/11/2013.  
Trials were included if they were (1) randomised control trials (2) studies delivered in hospital or 
community settings and (3) studies in English language. A hand search of relevant citations was 
also performed. 
Key findings  
Forty two studies were identified in which twenty six trials had statistically significant effect on 
adherence and twenty seven trials had significant effect on clinical outcomes of cardiovascular 
disease. The interventions included mainly patient education, collaboration between health care 
professionals, use of electronic devices and combined interventions. The interventions were 
found to be complex and included multiple components. Patient contact with a pharmacist was 
frequent and thus the interventions may be difficult to adapt into daily practice. Evidence- based 
data for pharmacy services remains weak but clearly pharmacists can have an impact through 
face-to –face patient education and telephone consultations. Further research is needed to 
evaluate the use of a motivational interview in the counselling session of a pharmacist and also to 
establish the continuity of pharmacy care in primary/secondary setting. Self reported adherence 
was the most widely used measure. The acceptable threshold remained 80% among the cardiac 
population.   
Conclusion 
Pharmacist interventions have been shown to be successful in enhancing adherence to 
cardiovascular medication and improving outcomes of cardiovascular diseases. Whilst, 
pharmacists play a fundamental role in primary and secondary prevention strategies, further RCT 
combining patient education with behaviour change is likely to reap further benefit in medication 
adherence.   
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Background 
 
Adherence has been defined as the “active, voluntary, and collaborative involvement of the 
patient in a mutually acceptable course of behaviour to produce a therapeutic result.”[1] Non 
adherence to medications has been documented to occur in > 60% of cardiovascular patients.[2]  
Primary non adherence (not initially filling the prescription) leads to a significant increase in  
one year mortality after hospitalization for myocardial infarction. [3] Secondary non adherence 
(failure to follow the instructions or to refill the prescription) has been shown to increase 
mortality, hospitalizations and costs.[2]  Therefore, it is crucial to promote adherence to improve 
outcomes in these groups of patients.   
 
Evidence-based data has demonstrated that pharmacists deliver clinical services that improve 
cost-effective quality of care in patients with cardiovascular diseases.[4]  It is estimated that  
poor adherence costs 100 billion USD annually in the U.S [5] and the cost of unwanted 
medications exceeds GBP100 million annually in the UK.[6] Pharmacists have an increasingly 
important role in improving adherence. This role can be achieved through services in hospitals 
(for example medicines reconciliation and monitoring) and in community (In the UK Medication 
Usage Reviews and the New Medicine Service, in the USA Medication Therapy Management 
and in Australia and Canada MedsCheck program). Moreover, pharmacists have reduced health 
care costs by minimizing adverse clinical events (hospitalizations, emergency room visits, etc.) 
and reduced outpatient visits.[4] Advanced patient care services, delivered by pharmacists, 
decrease drug-related morbidity and mortality.[4] Therefore, it is accepted that pharmacists are 
well placed to support patients with their medication use. This review aimed to add to existing 
evidence that illustrate improved health care delivery through the use of pharmacist-delivered 
patient care with a focus on cardiovascular diseases.   
 
Objectives 
  
 To establish if there is an effect of pharmacy service intervention, on improving 
adherence to medications and outcomes of cardiovascular diseases. 
 To identify types of interventions found to be effective in clinical trials in improving 
adherence to cardiovascular medication that could be implemented in practice. 
 
 
Methods 
 
Data resources  
 
A systematic search of articles published in peer-reviewed health-care related journals was 
performed. Data bases Pubmed central UK, Pubmed, Cochrane Library, CINHAL, PsycINFO, 
EMBASE, International Pharmaceutical Abstracts and Google Scholar were searched for the 
period from 01/01/1990 to 19/11/2013.  
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Search terms and search strategy 
 
The review commenced with three main key words “pharmacy service, adherence and 
cardiovascular disease”; with search restrictions to randomised control trials. The following key 
words were used (pharmacy care, adherence, cardiovascular disease or diseases), (pharmacy 
care, compliance, cardiovascular disease),(pharmaceutical care, adherence, cardiovascular 
disease), (pharmacists, cardiac disease, adherence), (adherence, pharmacists, cardiovascular 
disease), (adherence, pharmacist interventions, cardiovascular disease) in addition, search terms 
related to the type of diseases (hypertension or hyperlipidemia, or diabetes, or coronary heart 
disease, or heart failure).  Following this search other key words were generated from MeSH 
(medical subject heading) terms in PubMed and term mapping database EMBASE. The 
reference list of relevant papers was also searched in order to identify any additional studies.  
Duplicate articles were removed if they were found in the different databases.  Two articles 
published study protocols; therefore, the authors were contacted for results.  
 
Selection criteria 
 
Inclusion criteria: The articles were selected through screening of titles and abstracts.  The 
criteria for relevant studies were: (1) randomised control trials. (2) interventions aiming to 
enhance adherence to cardiovascular medications. (3) trials evaluating clinical outcomes of 
cardiovascular diseases in which adherence was the secondary outcome. (4) Studies delivered in 
hospital or community settings and (5) Studies in English language. 
 
Process of data extraction 
 
A table of details of each intervention was developed and it included a full description of the 
nature of each intervention and its duration. The interventions were compared for differences and 
similarities then the main categories were established. They were categorized according to the 
mode of delivery. A further table was developed for adherence measurements then similar 
measurements were grouped. Further variables assessed were arranged in tables to enable 
analysis these included setting, patient groups, outcome measures and study design. 
 
 
Results  
 
The search yielded a total number of 4095 citations, the titles and/or abstracts of these articles 
were reviewed, 111 full text articles matched the inclusion criteria and were retrieved 
electronically and/or paper copy for assessment 39 articles were identified.  The reference lists of 
the relevant 39 articles were also searched and an additional 3 articles were identified thus a total 
42 randomised controlled trials were included in this review (Figure-1). All stages; identification, 
selection and review of papers, data extraction and coding and analysis were undertaken by two 
independent authors (the first and second author). In regular meetings any discrepancies were 
discussed and procedures were refined.  
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The 42 articles that met the inclusion criteria were conducted in different countries USA (18 
articles), UK (3), Australia (3), Canada (4), UAE (2), Netherland (2), Belgium (2), Thailand (2), 
Northern Ireland (1), Portugal (1), Brazil (1), Spain (1), Jordan (1) and China (1). 
 
Studies design 
 
All the 42 studies included in this review were randomised controlled trials. Follow up for 
evaluation ranged from 3 months [7] to 36 months [8] however, in the majority of the studies the 
follow up period was either 6 months or 12 months.  Regarding the sample size this ranged from 
a sample size of 30 [9] to 4100 patients. [10] 
 
 
Patient/Disease groups  
 
Of the 42 trials that met the inclusion criteria 17 were conducted with patients with hypertension 
[7,8,11-25] 
, 10 [8,10,18,24-30] in diabetes, 7 [11,18,25,31-34] in dyslipidemia , 7 [35-41] in heart failure and 9 
[9,25,42-48]
 in coronary heart disease (CHD).  Five trials were aimed at populations with more than 
two co- morbidities or risk factors for cardiovascular disease.[8,11,18,24,25] One trial [11] studied 
patients with hypertension and dyslipidemia, another trial[18] studied patients with hypertension, 
dyslipidemia, diabetes and patients on anticoagulation therapy.  Furthermore, two trials [8,24] 
included patients with hypertension and diabetes and finally, one trial[25] studied patient 
populations for both primary and secondary prevention (hypertension, diabetes, dyslipidemia, 
coronary heart disease). 
 
Overview of goals of interventions and primary/secondary outcomes 
  
In 19 trials[8,9,11,16,19,23,24,32-35,37-39,42,43,46-48] the aim of the intervention was to enhance adherence 
and adherence was the primary outcome.  The remaining interventions measured adherence as a 
secondary outcome; the primary aims being to improve blood pressure control,[7,10,12-15,17,20-22,24] 
to improve glycaemic control and quality of care for diabetic patients,[26-30] or improve clinical 
outcomes in heart failure patients.[36,37,40,41]  Other secondary outcomes included reduction in 
multiple cardiovascular risk factors,[18,25] to improve use of guidelines for secondary prevention 
medication in patients with CHD [44, 45] and the achievement of target lipid levels and lipid 
control.[31] 
 
 
Setting  
  
In fifteen studies the principal setting for the intervention was a community pharmacy[7,15-
17,19,21,24,29,31-35,39,44]
, Fourteen studies the interventions were in hospital[11,12,23,26,27,30,37,38,40-
42,45,47,48]
 and nine [8,10,13,14,18,20,22,25,28]  in a clinic or primary care practice setting. In two 
trials[36,43] the intervention setting was patients’ home and in one trial[46] the intervention was 
delivered from both a hospital and community pharmacist setting.   
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Details of the intervention 
 
In accordance with eligibility criteria all interventions were conducted by a pharmacist. All 
interventions were complex and included multiple components.  However, they are described 
here according to the principal component of the intervention: 
 
 
A. Patient education 
Education by a pharmacist was delivered face-to-face, as a telephone contact or by a home visit. 
 
1-Face- to- face patient education  
Pharmacists provided education face-to face with a patient in twenty-one trials. It followed a pre-
specified structure in seven trials.[11,19,26,34,35,37,40]   In addition, the consultation focused on the 
disease and it’s prescribed medications.[11,18,21,24-29,32,37,39,40] The education also included 
discussions on medication related problems[17,24,28,32], lifestyle changes[12,17,18,21,24,25,27,29,44]  and  
reinforcement of adherence.[12,17,19,34,35,44]  
 
2- Patient education by telephone contact 
 
Telephone counselling was the principal intervention in four trials. Three of which,[9,30,42] had an 
initial inpatient consultation by a pharmacist regarding their medications, prior to discharge . 
This was followed by structured pharmacist telephone counselling to reinforce the information.  
In the fourth trial [47] there was no inpatient consultation prior to the telephone calls. All subjects 
in the intervention group received education and counselling on medication adherence.  The next 
call took place within 1 to 2 weeks or according to the need to support medication adherence. 
 
 
3-Home visits by pharmacists 
 
In two trials the intervention was delivered in home visits by a pharmacist.  These included 
education on the disease, life style issues and compliance with therapy. [36,43] Recommendations 
were also made to the physicians and local pharmacies for adherence aids. 
 
 
4-Motivational interviews 
 
In one trial [10] adherence counselling and medication management was delivered by clinical 
pharmacists trained in behavioural counselling approaches (motivational interviewing). Details 
of training, application and implementation were provided to ensure principles of motivational 
interviews were followed.  A road map was provided for the pharmacists, there was also an 
Page 6 of 27
http://mc.manuscriptcentral.com/ejhpharm
European Journal of Hospital Pharmacy
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
C
o
n
fid
en
tial: F
o
r R
eview
 O
n
ly
 
7 
 
assessment to check fidelity of the technique.  Two further trials mentioned motivational 
interviewing, but gave no details on how this component was implemented as part of the 
intervention [16, 30] also no assurance of fidelity of the technique.   
 
B. Collaboration between health care professionals 
 
1-Collaborative care 
 
In seven trials [8,13,14,22,31,38,45] the intervention involved collaboration between pharmacists and 
physicians or nurses, in a multidisciplinary approach.  Five[8,13,14,22,31] of these trials, addressed 
suboptimal regimens and poor adherence to medication through these collaborations. The other 
two trials [38,45] included joint intensive multidisciplinary team programmes that provided 
counselling on medications, videos and printed material to promote adherence.  
 
2-Communication between primary and secondary care 
 
One trial [46] evaluated the effect of facilitated communication between hospital and community 
pharmacists on medication adherence. The intervention group received enhanced in-hospital 
counselling, communication of discharge medications to community pharmacists and physicians, 
and ongoing assessment of adherence by community pharmacists.   
 
 
3- Combined intervention 
 
One trial [48] described as a multifaceted intervention lasted for 1 year following discharge and 
comprised of: (1) pharmacist-led medication reconciliation 7-10 days after discharge and at one 
month via an in-person clinic visit or telephone call; (2) Pharmacists’ provided the patient’s 
primary care clinician and/or cardiologist with their contact details for questions or clarifications; 
and (3) 2 types of voice messaging (educational and medication refill reminder calls). The 
medication refill calls were synchronized to when a medication refill was due.   
In a second trial[16] the participants received a number of interventions from the pharmacist 
which included: (1)Patient education and motivational interviewing; (2)electronic B.P home 
monitors; (3)home medicine review, dose administration aid and patient medication profile; (4) 
Refill reminders by SMS, telephone or mail. 
     
  
C. Use of electronic devices 
 
Four trials [7,15,20,33] used electronic devices, as the main intervention.  In two trials [7,20]  patients 
were provided with a fully automated Self Blood Pressure Monitor (SBPM) and told to perform 
2 B.P measurements each morning.   In one trial [15] patients were given a tool kit which included 
a B.P tracker and a pedometer. In another trial [33] patients were instructed on how to use a 
Medication Event Monitoring System MEMS (Medication bottles that contain a microelectronic 
chip that registers the date and time of every bottle opening). Patients’ and a pharmacist jointly 
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reviewed the electronically complied dosing history, educational reminders and a beep card that 
reminds the patient of the dosing time were also used.   
 
 
 
Additional components 
  
Additional components to the above interventions included; written information,[7,9,10,12,15,17-21,25-
27,30,36,37,39,40,42,44]
 providing patients with a diary,[17,37,40] a pocket medication card,[46]  
educational material, [10,46] education regarding the disease,[7,14,20] educational group activities,[8] 
recommending life style change,[31] recommendation to physicians, [7,13,15,22,42,45]  telephone 
calls,[19,20,22,25,28,41] home visit,[17] home medicine review,[16] pill box,[7,15,42,46,48] blisters,[11] 
electronic blood pressure home monitoring[10,16] and visual props and media videos.[38,45] 
  
Intervention duration  
 
The interventions were delivered on a weekly basis,[7,9,10,28,30,36,42,46,47] monthly basis,[8,11-13,17,19-
27,31-35,39-41,43,45,48]
 made at each prescription refill,[15,29,37] or arranged at physician 
visit,[18,24,27]according to pharmacist –determined patient need [14,44]and at one-time over 2 
days.[38]  
 
Measurement of adherence 
  
Diverse indirect measures of adherence were used in the trials these included; prescription refills, 
Medication Event Monitoring System (MEMS), pill counts and self reported adherence scaled 
questionnaires MARS and Morisky Scale.  Patients’ self reported adherence alone or in 
combination with other methods of measurement were widely used in the 42 trials. Thirty two 
trials measured adherence by a single approach and ten trials combined two adherence measures 
(Table 1). To distinguish adherence from non- adherence, consumption or refilling 80% of the 
prescribed medication doses was the widely accepted threshold among the trials.[8-
11,17,18,21,25,31,35,38,40,47,48]
 
 
Impact of interventions on adherence  
 
The review aimed to assess the effect of pharmacist service intervention on adherence. Twenty 
six trials[7-9,11-13,15-19,21,23,26,27,30,33-35,37,39-41,45,46,48] showed a statistically significant improvement 
on adherence to cardiovascular medication (Table 2) (Supplemental Table 3). Improvement in 
adherence across the 42 studies ranged from no statistically significant difference to 35% 
significant absolute change in adherence.  
 
Results indicate that face- to- face patient education by a pharmacist improved adherence in 
15/21 studies (Table 2) suggesting education could have a significant effect on adherence. 
Electronic devices showed success in enhancing adherence in 3/4 studies. These included the 
integration of home automatic blood pressure monitor, the use of electronic reminders (beep 
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card) and an electronic blood pressure tracker. In all these trials pharmacists also provided 
tailored educational services and patient follow up.  
 
One study [10] examined the use of motivational interviews by pharmacists, although it did not 
show significant results, details on the training of the pharmacists and the delivery and content of 
motivational interviews were provided. The authors report that high rates of treatment 
intensification and medication changes occurred in the control group leading to improvements in 
the studied outcomes among the controls.   
 
Telephone calls with patient education and advice had a success rate on improving adherence in 
2/4 trials that examined this type of intervention.  Two other trials [16,48] tested a combination of 
interventions to improve adherence, that also included medication refill reminders by telephone 
and showed significant results. Three of the seven interventions that evaluated a collaborative 
care approach to improve adherence had statistically significant results. One trial [46] examined 
the impact of communication between hospital and community pharmacies and showed 
significant results on adherence. 
 
Home visits by pharmacists did not have significant results on improving adherence to 
cardiovascular medication. In one trial [36] some possible reasons were provided by the authors 
that the intervention was brief and/or may have been too late in the disease course to evoke 
behaviour change. Also the pharmacists were not specialist in the disease studied.   
 
 
 
Effectiveness of interventions on outcomes of cardiovascular diseases 
 
Studied outcomes included; blood pressure control, HbA1c and/or fasting plasma glucose, Lipid 
profiles and LDL-C. Other outcomes were; reduction in 10 year Framingham risk score, costs 
and quality of life in addition to rehospitalisation, mortality and patient satisfaction with 
pharmacy services. Thirty nine trials evaluated the effect of pharmacy service interventions on 
outcomes of the diseases (Table 2) (Supplemental Table 3). Twenty seven trials had statistically 
significant results. In primary prevention from the 17 studies that studied hypertension 16/17 [7, 8, 
11-24]
 showed significant results and improvement in cardiovascular risk factors, in diabetes 6/10 
[8,18,24,26,29,30]
 improved glycaemia control for diabetic patients.  For dyslipidemia 4/6 [11,18,32,34] 
studies improved lipid profiles. In secondary prevention 4/7 heart failure trials had significant 
results [37, 39- 41) on improving clinical outcomes (mortality, rehospitalisation and quality of life) 
and in coronary heart disease 2/8 trials [9, 43] achieved significant results on clinical outcomes.   
 
Discussion 
 
This review aimed to assess the effect of pharmacist led interventions on adherence to 
cardiovascular medications.  Forty- two studies were identified of which twenty-six had a 
statistically significant and positive impact on adherence. Interpretation was complex due to the 
heterogeneity and multiplicity of the components. Results show that face-to-face patient 
counselling by a pharmacist as well as electronic interventions could be effective in improving 
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adherence. However, these interventions also involved other components. Evidence in other 
diseases has revealed that in person pharmacist and electronic interventions significantly 
improve adherence to medication.[49, 50] 
 
Motivational strategies and behavioural support have been shown to enhance adherence to 
medication.[51, 52] In addition, Motivational strategies are increasingly used in health care to 
promote behaviour change, due  to the need to focus on addressing the rising prevalence of 
chronic disease.  In this review only one trial studied the use of motivational interviews, by 
pharmacists, to improve adherence and outcomes and showed no significant results. 
Furthermore, two trials mentioned the use of motivational interviews in the pharmacist 
counselling session, but did not give further details on the fidelity of the technique. In their 
reviews, Thompson et al, 2011[53] and Dalem et al, 2012[54], have addressed the fact that 
behavioural interventions are effective in improving adherence. However, they did not focus on 
pharmacists’ role. For this reason, further evidence is needed to establish if and how motivational 
counselling in the pharmacy setting can lead to improvements on adherence. 
   
A telephone call or a reminder by a pharmacist has been found to be an effective approach to 
improve medication adherence in other diseases.[55-57] In the review by Cutrona et al, 2010 [58], 
which reviewed studies focusing on cardiovascular diseases, phone calls showed low success 
(38%). In our review 4/6 trials that evaluated this method had statistically significant results. 
Therefore, the use of telephone calls and SMS to improve adherence could be an effective 
approach.   
 
Interventions involving home visits by pharmacists have reported increased adherence to 
prescribed drugs, in an elderly population.[59, 60] Other studies, in contrast, which included a 
domiciliary assessment by a community pharmacist have found no effect on adherence,(61) 
studies in this review were not sufficient to provide evident conclusions.   
 
Although interventions in hospital setting had more significant results, four of these trials were 
conducted in military hospitals [11,23,26, 48] in which financial barriers to adherence are removed 
and patients’ attendance to appointments is high. Therefore, their results had limited 
generalisability and external validity.  In the review Cutrona et al, 2010 [58] the results 
demonstrate that in-person interventions at hospital discharge were more effective (67%) than 
clinic interventions (47%) and in-person pharmacist interventions were effective when held in a 
pharmacy (83%) and less effective in clinics (38%).  
 
Patients’ self reported adherence alone or in combination with other methods of measurement 
were widely used in the 42 trials. This is as recommended by NICE, 2009 guidelines that have 
identified that whilst other types of measures are useful for clinical trials of new drugs, self 
report is an appropriate tool for clinical practice.[62] A threshold of 80% to determine adherence 
from non adherence was accepted among the trials. This finding is similar to other observational 
studies measuring adherence [63-66].  A study, by Wu et al, 2009 [67], showed a positive 
relationship between level of medication adherence and event-free survival in patients with heart 
failure. The study found that patients, who take 88% of their prescribed medication doses and on 
88% of days take the correct dose, experienced a longer event-free survival than patients who are 
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less adherent.  Moreover, in an article by Ho et al , 2009  the authors report an analysis that 
suggests that there continues to be reductions in clinical outcomes with adherence levels beyond 
80% (eg, 80% to 100%), which suggests that the optimal level of adherence may be higher than 
current cut offs.[68]  Whilst 80% is generally accepted, there are few studies which examine 
levels of adherence against outcomes over a period of time. 
 
 “Can the interventions, in the reviewed studies, be adapted to clinical practice?” “What would 
be features of an intervention to improve adherence?” These questions should be addressed with 
caution. The interventions were complex and time intensive as concluded in previous reviews [69]. 
In addition, a wide variety of approaches have been employed in the pharmacy interventions. All 
the interventions included a range of multiple components underlining a belief that a single focus 
is less likely to be effective. Electronic devices did improve adherence, however, there could be 
the possibility of the Hawthorne effect. Face –to-face patient education by a pharmacist and 
possibly telephone counselling can be effective.  
 
This review has several limitations; there was a marked difference between the studies in their 
methodology, adherence measurement and duration of follow up. Studies were included from 
1990 up to 2013.  Definition of adherence was different in the studies conducted in the 1990s 
than those conducted in 2000s.  Moreover, some trials had only their methodology article 
published therefore; these trials were excluded due to no availability of the results. Descriptive, 
observational studies and studies published in other languages were not included. Strengths: the 
review included only randomised control trials, examined interventions in different settings with 
a focus on pharmacist interventions only.  
 
 
Conclusions 
 
Evidence- based data for pharmacy services remains weak, but studies have shown that 
pharmacists can have an impact through patient education and telephone counselling. 
Behavioural interventions delivered by pharmacists could have a positive effect, but further 
evidence is needed. Self reported adherence was the most widely used measure. The acceptable 
threshold remained 80% among the cardiac population.   
 
Recommendations 
 
 Personal contact or counselling by a pharmacist can be an effective method in enhancing 
adherence, but the frequency of contact to make the intervention more adaptable to practice 
needs to be further examined. Finally, further research is needed to evaluate the continuity of 
care in both primary and secondary settings and to promote links between hospital, community 
pharmacists and other health care professionals.  
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Table 1- Assessment of outcomes 
 
Adherence  

Indirect measures of adherence:  
From the 42 trials 32 trials measured adherence by a single adherence measurement 10 trials 
combined two adherence measures   
 
Single adherence measurement  Number of trials  
Refill data 10 trials[10,17,20,24,25,31,34,42,47,48]  
Self report questionnaires Seven trials [18,26,28,37,43-45]  
Morisky scaled questionnaire Six trials[7,12,14,22,23,30] 
Pill counts Five trials[11,13,21,27,41] 
MEMS (Medication Event Monitoring System) Two trials[33,35] 
The Hornes’s Medication Adherence Report 
Scale (MARS)  
Two trials[32,36] 
Combination of adherence measurement   
Refill data combined with self reported 
questionnaires 
Four trials[15,29,39,40]     
Refill data combined with the Morisky scale Two trials [8,46] 
Refill data combined with MEMS One trial[38] 
Refill data combined with MARS One trial [19] 
Refill data combined with pill counts One trial [9] 
Morisky Scale in addition to two scales 
originally developed in Australia the Tools for 
Adherence Behaviour Screening (TABS) and 
the medication refill data (MedsIndex score). 
One trial [16] 
 
 
For the Morisky scale, Morgado et al, 2010, Carter et al, 2009 and Calvert et al, 2012 used a 5 
item scale derived from the 4 item scale. Hunt et al, 2008, Zilich et al, 2005, Zhao et al, 2012, 
Lau et al, 2010 and Jarab et al, 2012 all used the 4 item scale.  Moreover, Obreli-Neto, 2011 
used the 4 item Morisky -Green test translated into Portuguese.  
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Table 2-Interventions and their mode of delivery 
 
Intervention  Trials Result on  
adherence  
 
Result on 
outcomes  
1-Patient 
education by 
pharmacist 
Lee et al  , 2006,  Bouvy et al , 2003, Morgado et al  , 2010, Al 
Mazroui et al  , 2009, Sadik et al, 2005, Alsani et al  , 2010, 
Murray et al, 2007, Mehuys et al, 2011, Taylor et al  , 2003, 
Jaffray et al, 2007, Blenkinsopp et al  , 2000, Sookaneknun et al  , 
2004, Phumipamorn et al, 2008 , Varma et al, 1999,  Odegard et 
al, 2005,  Park et al, 1996,  Lopez et al, 2006,  Zhao et al  , 2011,  
Planas et al, 2009 , Evans et al, 2010,  Eussen et al, 2010 
15(21) 
significant  
16(21) 
significant 
2-Telephone 
contact 
Yunsheng et al, 2010,  Faulkner et al, 2000,  Jarab et al, 2012, 
*Alsabbagh et al, 2012 
2(4)  
 
significant  
 
2(3) 
significant 
3-Use of 
electronic device 
 Zilich et al , 2005 (SMBP), Svarstad et al , 2009 (pedometer, 
blood pressure tracker), *Virijens et al, 2006 (Beep card), Mehos 
et al, 2000 (SMBP) 
3(4)  
 
significant 
 
3(3) 
significant 
 
4-Home visit Holland et al, 2007,  Peterson et al , 2004 
 
0 (2) 
 non 
significant 
1(2) 
significant  
5-Collaborative 
care 
Carter et al  , 2008, Hunt et al  , 2008, Villeneuve et al  , 2010, 
Gwadry-Sridhar et al  , 2005, Edworthy et al, 2007, Obreli Neto 
et al, 2011 , Carter et al, 2009. 
3(7)  
 
significant  
 
4(7) 
significant 
 
6-Motivational 
interviews 
Heisler et al, 2012. 1(1)  
Non 
significant  
 
0(1) 
Non 
significant 
7- 
Communication 
between primary 
and secondary 
care 
*Calvert et al, 2012.  1(1) 
significant 
 
0(0) 
 
8-Combined  
interventions 
Ho et al, 2013, Lau et al, 2010. 2(2) 
significant  
1 (2) 
Significant  
 Total  26/42 trials 27/39 trials  
*Trials that did not evaluate clinical outcomes 
  Statistical significance at p- value 0.05 
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Supplemental Table 3- Effect of pharmacy care on adherence and outcomes 
 
Study  Trial length  Effect on adherence 
 
Effect on outcomes of the diseases  
no. of 
patients  
Lee et al, 2006 
(11) 
 
 USA 
FAME study  
14 months  
159  
35.5%  absolute change in adherence  p<0.001,  persistence 
was sustained in the pharmacy care group p<0.001 
Significant improvements in systolic 
BP 133.2 mmHg to 129.9mmHg 
(P=.02) and LDL-C 91.7 to 86.8 mg/dl 
P=.001). 
Significant reductions in systolic BP in 
the pharmacy care group (−6.9 mm 
Hg; 95% CI, −10.7 to −3.1 mm Hg) vs 
the usual care group,(−1.0mmHg; 
95%CI, −5.9 to 3.9mmHg; P=.04), but 
no significant between-group 
differences in LDL-C levels or 
reductions. 
Bouvy et al, 
2003(35)  
 
Netherland  
6 months  
152  
Intervention group did not use diuretics for 140/7656 days, 
control group 337/6196 days (relative risk 0.33, 95% CI). 
There were no significant differences 
in rehospitalizations, mortality, or 
disease-specific quality of life between 
groups. 
Morgado et al  , 
2010(12)  
 
Portugal  
9 months  
197 
Medication adherence was 57.6% at baseline in the 
Intervention Group and 74.5% at the end of the study p=0.012. 
Difference in low adherence 22.3% Intervention Group vs 
43.8% Control Group  P=0.0017 
Significant lower systolic blood 
pressure -6.8 mmHg (P = 0.006) and 
diastolic blood pressure -2.9 mmHg  
(P = 0.020) levels were observed in 
the intervention group 
Yunsheng et al  , 
2010 (42)  
 
USA 
 
Sep 2000-
August 2005. 
689 
No significant effect  0.88 in the Pharmacy Intervention and 
0.90 in the Usual Care p=0.51 
At one year, 65% in the Pharmacy 
Intervention condition and 60% in the 
Usual Care condition achieved an 
LDL-C level < 100 mg/dL (P = .29) 
the result was not statistically 
significant.  
Carter et al  , 
2008 (13) 
 
USA     
9 months  
179 
At baseline medication adherence was significantly better in the 
control group 89% vs 71% in the Intervention group, after 9 
months  92% control and 94% intervention group p=0.396. 
The mean adjusted difference in SBP 
was 8.7 (95% CI: 4.4, 12.9) mm Hg, 
while the difference in DBP was 5.4 
(CI: 2.8, 8.0) mm Hg. BP was 
controlled in 89.1% of patients in the 
intervention group and 52.9% in the 
control group p<0.001 significant 
result  
Al Mazroui et al  
, 2009 (26) 
 
UAE 
 
12 months  
240 
Non adherence was decreased from 48.3% at baseline 
Intervention Group  to 21.4%,  49.1% in the Control group to 
32.5%  p<0.05 
Significant reductions (P <0.001) in 
mean values (baseline vs. 12 months 
of HbA1c [8.5% vs. 6.9% systolic 
131.4 mmHg  vs. 127.2 mmHg and 
diastolic blood pressure 85.2 mmHg 
vs. 76.3 mmHg were observed in  the 
intervention group; no significant 
changes were noted in the 
control group. 
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Hunt et al, 
2008(14) 
 
USA 
 
12 months  
463 
 
No difference between the groups 67% IG vs 69% Control 
Group.  A small non significant result increase from baseline 
61% to 67%in the Intervention Group. 
Significantly lower systolic (p =
0.007) and diastolic (p = 0.002) blood 
pressures compared to control (137/75 
mmHg vs. 143/78 mmHg). In 
addition, 62% of intervention subjects 
achieved target blood pressure 
compared to 44% of control subjects 
(p = 0.003) 
Zilich et al, 
2005(7)
 
 USA 
HOME study  
3 months  
125 
 No significant differences at any time between the groups, 
p=0.38, significant increase in adherence in the High- Intensity 
group 61.3% at baseline to 87.7% end of the study  p=0.004. 
From baseline, SBP declined 
13.4mmHg in the High-Intensity 
group and 9.0mmHg in the Low- 
Intensity group. At the final visit, the 
difference in SBP/DBP change 
between the High-Intensity and Low -
Intensity group was -4.5/-3.2mmHg 
(P=.12 for SBP and P=.03 for DBP). 
Diastolic B.P significant result  
Holland et al, 
2007 (36) 
 
UK 
 
 
6 months  
 
293 
 
No evident differences, final adherence scores were marginally 
higher in the intervention group. P=0.68. 
134 admissions occurred in the 
intervention group compared with 112 
in the control group (rate ratio=1.15, 
95% confidence interval; P=0.28), 30 
intervention patients died compared 
with 24 controls (P=0.54). The 
difference was statistically non 
significant. 
Sadik et al , 
2005 (37) 
 
UAE 
 
12 months  
 
221 
No. of patients with self reported compliance was 85 vs 35 in 
Intervention Group and Control Group respectively and at 
baseline was 33 vs 32, P<0.05.  
Intervention patients showed 
significant (P <0.05) improvements in 
a range of summary outcome measures 
exercise tolerance, forced vital 
capacity, health related quality of life.  
Peterson et al, 
2004 (43) 
 
Australia   
 
6 months  
 
94 
 
No significant result 
Self-reported patient compliance with medication did not 
change over the course of the study, and total cholesterol levels 
were not significantly related to self-reported patient 
compliance either at the baseline (P > 0·50) or at follow-up 
 (P > 0·30). 
 
The reduction over the course of the 
study in cholesterol levels within the 
intervention group was statistically 
significant (4·9 ±0·7 to 4·4 ± 0·6, P < 
0·005), whereas there was no change 
within the control group (P = 0·26). 
The reduction in total cholesterol in 
the intervention group should translate 
to an expected 21% reduction in 
cardiovascular mortality risk and a 
16% reduction in total mortality risk – 
more than twice the risk reduction 
achieved in the control group. 
Villeneuve et al, 
2010(31)  
 
Canada 
 
 
12 months 
108 
collaborative 
care patients 
(CC). 
117 
Usual care 
patients (UC). 
Persistence with lipid-lowering 
medication at 12 months 
CC 
86% 
UC 
81% 
1.03 (0.94 
to 1.19) 
Adherence to lipid-lowering 
medication at 12 months (≥ 80%) 
CC 
72% 
UC 
68% 
1.04 (0.90 
to 1.27) 
 
 
No significant clinical impact on lipid 
control in patients with dyslipidemia. 
At 12 months, patients in the 
collaborative care group had an 
additional reduction of  0.2 mmol/L in 
LDL cholesterol (95% CI −0.3 to 
−0.1) relative to patients in the usual 
care group. However, the adjusted 
difference was not statistically 
significant (−0.05 mmol/L, 95% CI 
−0.3 to 0.2). Slight difference in 
adherence. 
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Gwadry-Sridhar 
et al, 2005(38) 
 
USA 
 
12 months or 
until death. 
134 
 
No statistically significant difference in compliance.  A significant effect on knowledge 
Health related quality of life The 
composite end points (mortality, 
hospital readmission, emergency 
visits) occurred in 60% control, 67% 
intervention but was not statistically 
significant. 
Murray et al, 
2007 (39) 
 
USA 
12 months  
314 
During the 9-month intervention period, medication adherence 
was 67.9% and 78.8% in the usual care and intervention 
groups, respectively (95% CI). However, these salutary effects 
dissipated in the 3-month post intervention follow-up 
period.10.9% difference in adherence between the intervention 
and the control group adherence became 66.7% and 
70.6%difference 3.9% 
Emergency department visits and 
hospital admissions were 19.4% less 
annual direct health care costs were 
lower ($–2960)  in the intervention 
group.  
 
Svarstad et al, 
2009 (15) 
 
 USA 
TEAM trial 
 
6 months-one 
year 
576 
The intervention group reported lower non adherence (18% vs 
29%, p= 0.02). 
Had better BP control (55% vs 36%, p 
0.001)  
 
Aslani et al , 
2010(32) 
 
Australia 
9 months 
142 
No significant result  Patients significantly lowered their 
cholesterol levels p<0.01 
5.10 mmole/l Intervention Group,4.81 
CG end of study 4.63 Intervention 
Group and 4.80 Control Group 
Lau et al, 
2010(16)  
 
 
Australia  
HAPPY trial 
6 months 
395 
completed the 
study 
Hidden group 
178 
It cannot be concluded that the intervention improved 
adherence in comparison to the control group. On the Morisky 
scale, the proportions of adherent participants in each group 
increased significantly over six months but the difference 
between groups was not statistically significant. 
Significant result in differences between the intervention and 
the control group in the tabs adherence score p=0.046, and 
significant results in the intervention between the control and 
the intervention group in the Medsindex score p=0.046. 
Significant reduction in systolic BP 
occurred in both groups (PCG: 9.97 
mmHg, p<0.001; UCG: 4.61 mmHg, 
p<0.01) and was significantly greater 
in the PCG (p=0.02) mean reduction in 
B.P 10mmHg.  
Vrijens et al, 
2006 (33)  
Belgium  
1 year  
392 
6.5% increase in post baseline adherence p<0.001 and 13% 
increase in persistence p=0.002 
 
 
 
Did not evaluate outcomes 
Phumipamorn et 
al , 2008 (27) 
 
Thailand 
 
8months 
135  
diabetic  
Muslims 
The percent pill count was increased in the study group p= 
0.004 (+6.8 vs -2.8) but not in the control.  
No significant difference in A1c 
between the study and control group. 
P=0.56. Total cholesterol and LDL-C 
improvements were greater in the 
study group than the control. P=0.002 
Sookaneknun et 
al, 2004(17) 
 
Thailand 
6 months  
 
235 
The treatment group showed significantly better adherence 
p=0.014 Significantly better adherence increased by 58% to 
70%  
The study group had significant 
reduction in systolic and diastolic 
blood pressure p=0.037, 0.027, 
respectively.  
Taylor et al, 
2003(18)  
 
USA 
12months 
81 
The percentage of patients with medication compliance scores 
of 80%-100% increased by 15% in the intervention group but 
not in the control, however compliance scores did not differ 
significantly between the groups.  
The percentage of patients responding 
to hypertension, diabetes, dyslipidemia 
and anticoagulation therapy increased 
significantly in the intervention group 
and declined in the control group. 
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Jaffray et al  , 
2007(44)  UK 
The MEDMAN 
Study. 
12 Months 
1614 
 
No significant effect on self reported compliance.  
 
No statistical significant differences in 
outcomes. 
Blenkinsopp, 
2000(19) 
 
UK 
6 months 
282 
180 
completed the 
study 
At baseline the percentage of patients who were adherent was 
very similar in the two groups 52.3% and 51% in the 
Intervention Group  and Control Group respectively post study 
this increased to 62.9% and 50%, p<0.05. 
Patients whose blood pressure was 
uncontrolled prior to the study were 
more likely to become controlled in 
the intervention group (P<0.05).  
Edworthy et al, 
2007(45) 
 
Canada 
 
  
19 months 
 
2643 
 
 
 
Adherence in the intervention group was greater than in the 
control group only for beta-blockers (89% versus 80%; P<0.01) 
and lipid-lowering agents (83% versus 78%; P<0.05). 
Total days in hospital per patient were 
similar (10.9 days in the usual care 
group versus 10.2 days in the 
intervention group; P not significant). 
Crude mortality 
was 6.2% and 5.5% in the usual care 
and intervention groups, respectively, 
with no significant difference (P=0.15) 
rehospitalization rates results were not 
significant. Post hoc analysis an 
important difference in the number of 
days in hospital might have been 
achieved by the program with 
considerable cost savings p<0.05)  
Varma et al, 
1999 (40) 
 
 Northern Ireland  
12months  
83 
 
No significant change in adherence from self reports, from 
computerized patient drug records an increased number of 
patients in the intervention group were compliant p=0.039. 
Group A patients showed improved  
exercise capacity, significant 
improved knowledge of their drug 
therapy, fewer hospital admissions 
p=0.006.  
Odegard et al  , 
2005(28) 
 
USA 
 
12months 
77 
Self report medication adherence was not significantly 
improved by the intervention. 
The mean HbA1c did not differ 
between groups p=0.61, a reduction in 
HbA1c was noted for both groups over 
time compared with baseline 
(p=0.001). 
Mehos et al  , 
2000 (20) 
 
USA 
 
6 months 
41 
Mean compliance with antihypertensive therapy was 89% in 
the control and 82% in the intervention group p=0.29. 
Reductions in systolic and diastolic 
pressures were significantly reduced 
from baseline in the intervention  
group (17.0 and 10.5 mm Hg 
p<0.0001) but not in the control group 
(7.0 and 3.8 mmHg, p=0.12 and 
p=0.09) 
Park et al, 1996 
(21) 
 
USA 
Oct. 1993-
May1994. 
And 
Oct.1994-
1995. 
64 
Compliance for visits 2 through 4 showed no difference among 
the groups , however compliance was greater on visits 2, 3 
compared with control 96.7+-4 vs 86.0+- 20.7 p=0.025  
Blood pressure control was 
significantly improved in the study 
group. 
Mehuys et al, 
2011(29) 
 
Belgium  
 
6 months 
288 
No evident result: prescription refill rates was very high in both 
study groups (control group: median = 94.7%; intervention 
group: median = 99.7%). Moreover, a substantial proportion of 
patients had adherence rates of more than 100%, even up to 
200% . Data were considered unsuitable for further analysis. 
With respect to the self-reported adherence, both study groups 
declared themselves to be very adherent to their diabetes 
medication. 
 
The intervention significantly 
reduced HbA1c (between-group 
difference 0.5%, P = 0.009). 
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Obreli-Neto et al  
, 2011(8) 
 
Brazil 
36 Months 
 
200 
Significant improvement 50.5% of adherent patients at baseline 
vs 83.5% of adherent patients after 36 months p<0.001no 
significant changes in the control group.  
Significant improvements in the 
number of patients reaching adequate 
values for their blood pressure (26.8% 
at baseline vs. 86.6% after 36-months; 
P< 0.001), fasting glucose (29.9% at 
baseline vs. 70.1% after, 36 months; 
P< 0.001), A1C hemoglobin (3.3% at 
baseline vs. 63.3% after 36 months; 
P<0.001 
Lopez et al, 
2006(41) 
 
 Spain 
12 months  
134 
Difference in compliance between the intervention and control 
group. 88.2% vs 60.5% at 2 months, 91.1% vs 69% at 6 months 
and 85% vs 73.9%.  
32.9% fewer patients in the 
intervention group were admitted 
again vs. the control group. The mean 
days of hospital stay per patient in 
the control group were 9.6 (SD = 18.5) 
vs. 5.9 (SD = 14.1) in the intervention 
group 
Faulkner et al, 
2000 (9) 
 
USA 
24 months  
30  
Compliance was significantly better in the intervention group 
up to 2 years p<0.05 63% vs 39% and 48% vs 23%. 
Lipid profile results were significantly 
better in the intervention group p<0.05 
up to 2 years after start of therapy than 
in the control group for all parameters 
except high density lipoprotein. 
Calvert et al  , 
2012 (46) 
 
USA 
6 months  
143 
Self report adherence no difference between intervention and 
control. Using Proportion of Days Covered adherence to both 
statins and beta blocker there was better adherence in the 
intervention vs control but result not statistically 
significant(53%-38% p=0.11).  
Adherence to β-blockers was statistically Significant (p=0.03) 
in intervention versus control (71% vs 49%, respectively.  
Did not evaluate outcomes  
Carter et al  , 
2009(22)  
 
USA  
6 months  
402 
 
The percentage of patients with poor self-reported medication 
adherence declined from 18.7 ± 22.0% to 14.7 ± 20.9 in the 
control group and from 17.3 ± 27.5 to 14.6 ± 25.4% in the 
intervention group (p=0.602 and p=0.979, respectively). 
Mean BP decreased 
6.8/4.5 and 20.7/9.7 mm Hg in the 
control and intervention groups, 
respectively, (p<0.05), BP was 
controlled in 29.9% of patients in the 
control group and 63.9% in the 
intervention group  p<0.001) 
Zhao et al, 2012 
(23) 
 
China  
6 months 
278 
Significant difference in percentage of patients with low 
adherence  24.8% intervention group  vs 41.7% control group 
p=0.0014 
BP was controlled among 
significant patients more in 
Intervention Group (76.4%) than in 
Control Group  (50.6%) (P = 0.0000). 
Significant lower SBP (-8.5 mmHg, P 
= 0.0001) and DBP (-4.7 mmHg, P = 
0.0013) levels were observed in 
Intervention Group. 
Planas et al  , 
2009 (24) 
 
USA 
9 months 
52 
Adherence increased by 7% in the intervention group but the 
result was statistically not significant.  
The mean intervention group SBP 
decreased 17.32 mm Hg, whereas the 
mean control group SBP level 
increased 2.73 mm Hg (P = 0.003) 
Evans et al  , 
2010 (25) 
 
Canada 
6 months  
176 
The proportion of patients exhibiting statin adherence of 80% 
or greater did not significantly differ between groups at study 
end (73.1%] and 80.0% respectively, p=0.333). However, 
85.2% in the follow-up group continued with statin therapy at 
the end of the study compared with 67.0% in the single-contact 
group (p=0.005). 
 
Neither the mean reduction in 10-year 
risk (-2.68 for the follow-up group and 
-1.25 for the single-contact group, 
one-tailed p=0.098) nor individual risk 
factors were significantly different 
between groups. 
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 Heisler et al, 
2012 (10) 
 
 USA  
14 months 
4100 
More effective in increasing medications than improving 
medication adherence.  
The mean SBP decrease from 6 
months before to 6 months after the 
intervention period was approximately 
9 mm Hg in both arms. Mean SBPs of 
eligible intervention patients were 2.4 
mm Hg lower (P <0.001) immediately 
after the intervention than those 
achieved by control patients. 
Eussen et al, 
2010(34) 
 
Netherlands  
12 months 
1016 
Significantly lower rate of discontinuation within 6 months 
after initiating therapy versus usual care (95% CI). No 
significant difference between groups was found in 
discontinuation at 12 months (95% CI). Median Medication 
Possession Ratio was very high (>99%) in both groups and did 
not differ between groups. 
In the pharmaceutical care patients 
both mean cholesterol and LDL-C 
levels declined significantly during the 
study. A significant negative 
association between the Medication 
Possession Ratio and total cholesterol 
p=0.002 
Alsabbagh et al, 
2012(47) 
Canada 
6 months  
95 
The mean adherence to all recently initiated cardiovascular 
medications combined was 88.8% in the intervention group and 
89.9% in the usual care group ( P = 0 .73). 
 
Did not evaluate outcomes 
 Jarab et al, 
2012(30) 
 
Jordan  
6 months  
171 
The intervention group compared with the usual care group had 
small but statistically significant improvements in the 
secondary measures self-reported medication adherence, and 
self-care activities.  
Patients in the intervention group had 
a mean reduction of 0.8% in A1c 
versus a mean increase of 0.1% from 
baseline in the usual care group (P = 
0.019). Between-group differences in 
changes in the secondary measures of 
HDL-C and body mass index were not 
significant. 
Ho et al, 2013(48) 
 
USA 
12 months  
253 
241 (95.3%) completed the study (122 in Intervention and 119 
in Usual Care). In the Intervention group, 89.3%of patients 
were adherent compared with 73.9%in the Usual Care group (P 
= .003). Mean Proportion of Days Covered was higher in the 
Intervention group (0.94 vs 0.87; P< .001). A greater 
proportion of intervention patients were adherent to clopidogrel 
(86.8%vs 70.7%; P = .03),statins (93.2%vs 71.3%; P < .001), 
and ACEI/ARB (93.1% vs 81.7%; P = .03) but not β-blockers 
(88.1%vs 84.8%; P = .59).  
There were no statistically significant 
differences in the proportion 
of patients who achieved BP and 
LDL-C level goals. 
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